Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines

Breast Cancer Research and Treatment

Volumn 48, Issue 3, 1998, Pages 195-203

  Han, Edward Kyu Ho ^a   Arber, Nadir ^a   Yamamoto, Hirofumi ^a   Lim, Jin T E ^a   Delohery, Tom ^b   Pamukcu, Rifat ^c   Piazza, Gary A ^c   Xing, Wang Qiu ^a   Weinstein, I Bernard ^a,d  

^a Columbia University ^*  (United States)

^b Flow Cytometry Core Facil Mem S   (United States)

^c Cell Pathways Incorporated   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

Apoptosis; Cyclins; p21(WAF1); Sulindac

Indexed keywords

CYCLIN D1; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE; SULINDAC; SULINDAC SULFIDE;

APOPTOSIS; ARTHRITIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL STRAIN MCF 7; COLON CARCINOGENESIS; COLON POLYP; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EARLY RESPONSE GENE; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; POLYPOSIS; PRECANCER; PRIORITY JOURNAL; RECURRENT DISEASE; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL DIVISION; CELL LINE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; EPITHELIAL CELLS; FEMALE; HUMANS; SULINDAC;

EID: 0031946201     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005924730450     Document Type: Article

References (25)

1. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313-1316, 1993
2. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157: 175-179, 1989
3. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonie tumours in mice. J Pathol 156: 341-347, 1988
4. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55: 1464-1472, 1995
5. Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, Sperl GJ, Pamukcu R, Ahnen DJ: Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 87: 1259-1260, 1995
6. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ: Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57: 267-271, 1997
7. Shen TY, Ham EA, Cirillo VJ et al.: Prostaglandin synthetase inhibitors. In: Robinson HJ, Vane JR (eds) Prostaglandin Synthetase Inhibitors. Their Effects on Physiological Functions and Pathological States. Raven Press, New York, 1974. pp 18-31
8. Duggan DE, Hooke KF, Risley EA et al.: Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 201: 8-13, 1977
9. Goldberg Y, Nassif II, Pittas A, Tsai L-L, Dynlacht BD, Rigas B, Schiff SJ: The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12: 893-901, 1996
10. Piazza GA, Kulchak Rahm A, Kruntzch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukeu R, Ahnen DJ: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995
11. Shiff JS, Koustos MI, Qiao L, Rigas B: Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188, 1996
12. Shiff SJ, Qiao L, Tsai L-L, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenomacarcinoma cell. J Clin Invest 96: 491-503, 1995
13. Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994
14. Sherr CJ: Mammalian G1 cyclins. Cell 79: 551-555, 1994
15. Gu Y, Turck CW, Morgan DO: Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond) 366: 707-710, 1993
16. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-98, 1994
17. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature (Lond) 366: 701-704, 1993
18. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Buurrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Kohn KE, Elledge SJ, Kinzler KW, Vogelstein B: WAFI/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994
19. Calaf G, Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483-492, 1995
20. Han EK-H, Sgambato A, Jiang W, Zhang Y-U, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein IB: Stable over-expression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 10: 953-961, 1995
21. kipl, inhibits growth, and enhances apoptosis. Cell Growth Diff 7: 699-710, 1996
22. WAF1/CiP1 induces growth arrest, giant cell transformation and apoptosis in human breast carcinoma cell lines. Oncogene 11: 1899-1905, 1995
23. CIP1/Waf1 expression in human breast epithelial cells. Oncogene 11: 253-261, 1995
24. Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M: Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 9: 2663-2674, 1994
25. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-7559, 1990